Menopur (Menotrophin)

Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). These hormones bind to specific receptors on ovarian cells, triggering signalling pathways that promote follicle recruitment, growth, estrogen production, and final maturation of the dominant follicle, thereby mimicking the natural hormonal surge required for ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian response, treatment protocol, and underlying condition. Dosing is adjusted using ultrasound monitoring and hormone measurements throughout the stimulation cycle.

Menopur is contraindicated once pregnancy is confirmed because it can affect the hormonal environment of an established pregnancy. Limited data are available for breastfeeding; therefore, use during lactation is generally not recommended unless the benefit outweighs potential risk and is approved by a healthcare professional.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Menopur provides a fixed combination of FSH and LH activity, whereas some alternatives contain only FSH (e.g., follitropin alfa) or separate LH preparations. The combined formulation can be advantageous for patients who benefit from both hormones, potentially reducing the need for additional LH supplementation during stimulation.

Menopur must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain to preserve potency.

Menopur is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or the patient after proper instruction. The injection site should be rotated to minimise local irritation.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and respiratory distress, as well as thromboembolic events and severe allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these symptoms develop.

Menopur should not be used by women who are already pregnant, have uncontrolled thyroid disease, active hormone‑sensitive cancers, or severe ovarian cysts. It is also contraindicated in patients with known hypersensitivity to menotrophin or any excipients in the formulation.